Spring Bank, Gilead to test HBV combo

Spring Bank Pharmaceuticals Inc. (Milford, Mass.) said it will collaborate with Gilead Sciences Inc. (NASDAQ:GILD) to conduct a Phase II trial of Spring Bank's SB 9200 plus Gilead's Viread tenofovir disoproxil fumarate to treat HBV. Neither partner responded to inquiries about a timeline.

SB 9200 is a small molecule targeting DEAD box polypeptide 58 ( DDX58; RIG-1) and caspase recruitment domain family member 15 ( CARD15; NOD2). Spring Bank is developing the therapy to treat HBV and HCV. ...